FR-167653, a selective p38 MAPK inhibitor, exerts salutary effect on liver cirrhosis through downregulation of Runx2

Laboratory Investigation

Volumn 87, Issue 6, 2007, Pages 591-601

  Hattori, Shinji ^a   Dhar, Dipok K ^b   Hara, Nobumasa ^a   Tonomoto, Yasuhito ^a   Onoda, Toshinao ^a   Ono, Takashi ^a   Yamanoi, Akira ^a   Tachibana, Mitsuo ^a   Tsuchiya, Mikako ^a   Nagasue, Naofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Fibrosis; Hepatic stellate cell; p38 MAPK; Runx2; Smad; TGF

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; ALPHA SMOOTH MUSCLE ACTIN; CARBON TETRACHLORIDE; HYDROXYPROLINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OLIVE OIL; SMAD4 PROTEIN; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; MYOFIBROBLAST; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; STELLATE CELL;

ANIMALS; CARBON TETRACHLORIDE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; PYRIDINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 34249082398     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700539     Document Type: Article

References (37)

1. Guyot C, Lepreux S, Combe C, et al. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006;38:135-151.
2. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004;84:153-159.
3. Kinnman N, Francoz C, Barbu V, et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003;83:163-173.
4. Tuchweber B, Desmouliere A, Bochaton-Piallat ML, et al. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab Invest 1996;74:265-278.
5. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001;34:859-867.
6. Sugiyama M, Ichida T, Sato T, et al. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Gastroenterology 1998;114:550-558.
7. Cho JJ, Hocher B, Herbst H, et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000;118:1169-1178.
8. Kinnman N, Goria O, Wendum D, et al. Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest 2001;81:1709-1716.
9. Komuves LG, Feren A, Jones AL, et al. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem 2000;48:821-830.
10. Sudo K, Yamada Y, Moriwaki H, et al. Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine 2005;29:236-244.
11. Parsons CJ, Bradford BU, Pan CQ, et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 2004;40:1106-1115.
12. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
13. Tsukada S, Westwick JK, Ikejima K, et al. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem 2005;280:10055-10064.
14. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004;23:4198-4208.
15. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:747-754.
16. Xiao G, Jiang D, Thomas P, et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 2000;275:4453-4459.
17. Wada T, Furuichi K, Sakai N, et al. A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats. J Am Soc Nephrol 2000;11:1534-1541.
18. Matsuoka H, Arai T, Mori M, et al. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002;283:L103-L112.
19. Tsutsumi R, Kamohara Y, Eguchi S, et al. Selective suppression of initial cytokine response facilitates liver regeneration after extensive hepatectomy in rats. Hepatogastroenterology 2004;51:701-704.
20. Yao HW, Yue L. Effect and mechanisms of FR167653, a dual inhibitor of TNF-alpha and IL-1, on BCG plus LPS induced-liver injury. Inflamm Res 2005;54:471-477.
21. Selberg O, Bottcher J, Tusch G, et al. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997;25:652-657.
22. Burt AD. Pathobiology of hepatic stellate cells. J Gastroenterol 1999;34:299-304.
23. Reeves HL, Dack CL, Peak M, et al. Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. J Hepatol 2000;32:465-472.
24. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584.
25. Cao Q, Mak KM, Lieber CS. DLPC decreases TGF-beta1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2002;283:G1051-G1061.
26. Varela-Rey M, Montiel-Duarte C, Oses-Prieto JA, et al. p38 MAPK mediates the regulation of alpha1(I) procollagen mRNA levels by TNF-alpha and TGF-beta in a cell line of rat hepatic stellate cells(1). FEBS Lett 2002;528:133-138.
27. Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;270:2008-2011.
28. Schnabl B, Bradham CA, Bennett BL, et al. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology 2001;34:953-963.
29. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 1999;274:27161-27167.
30. Bertrand-Philippe M, Ruddell RG, Arthur MJ, et al. Regulation of tissue inhibitor of metalloproteinase 1 gene transcription by RUNX1 and RUNX2. J Biol Chem 2004;279:24530-24539.
31. Lee KS, Hong SH, Bae SC. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene 2002;21:7156-7163.
32. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103:5060-5065.
33. Stock M, Schafer H, Stricker S, et al. Expression of galectin-3 in skeletal tissues is controlled by Runx2. J Biol Chem 2003;278:17360-17367.
34. Dean JL, Sarsfield SJ, Tsounakou E, et al. p38 Mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation. J Biol Chem 2003;278:39470-39476.
35. Kitamura K, Nakamoto Y, Akiyama M, et al. Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine- induced murine liver fibrosis. Lab Invest 2002;82:571-583.
36. Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000;119:466-478.
37. Kawaguchi K, Sakaida I, Tsuchiya M, et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004;315:187-195.